camptothecin has been researched along with dexrazoxane in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bist, G; Kadayat, TM; Kwon, Y; Lee, ES; Lee, HJ; Park, S; Shrestha, A; Thapa Magar, TB | 1 |
| Agu, RU; Feridooni, T; Mac Donald, C; Shao, D; Yeung, P | 1 |
3 other study(ies) available for camptothecin and dexrazoxane
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Topics: Antineoplastic Agents; Apoptosis; Benzofurans; Biocatalysis; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; DNA; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Design; Humans; Pyridines; Structure-Activity Relationship; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2017 |
Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cardiovascular Agents; Cell Death; Cell Line; Cell Survival; Dexrazoxane; Diltiazem; Doxorubicin; Humans; Inhibitory Concentration 50; Irinotecan; Losartan; Myoblasts; Rats | 2013 |